The Pharmacological or Genetic Blockade of Endogenous De Novo Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells
Authors:
Open Access
- 13 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Ovarian cancer(OC) is a serious threat to women worldwide. Peritoneal dissemination, ascites and omental metastasis are typical features for disease progression, which occurs in a micro-environment that is rich in high-energy lipids. OC cells require high amounts of lipids for survival and growth. Not only do they import lipids from the host, they also produce lipidsde novo. Inhibitors of fatty acid(FA) synthase(FASN) – the rate-limiting enzyme of endogenous FA synthesis that is overexpressed in OC – induce growth-arrest and apoptosis, rendering them promising candidates for cancer drug development. However, cancer researchers have long hypothesized that the lipid deficiency caused by FASN inhibition can be circumvented by increasing the uptake of exogenous lipids from the host, which would confer resistance to FASN inhibitors. In contrast to a very recent report in colorectal cancer, we demonstrate in OC cells (A2780, OVCAR3, SKOV3) that neither FASN inhibitors (G28UCM, Fasnall) nor FASN-specific siRNAs can stimulate a relief pathway leading to enhanced uptake of extrinsic FAs or low density lipoproteins (LDLs). Instead, we observed that the growth-arrest due to FASN inhibition or FASN knock-down was associated with significant dose- and time-dependent reduction in the uptake of fluorescently labeled FAs and LDLs. Western blotting showed that the expression of the FA receptor CD36, the LDL receptor(LDLR) and the lipid transport proteins fatty acid binding proteins 1–9 (FABP1–9) was not affected by the treatment. Next, we compared experimental blockade of endogenous lipid production with physiologic depletion of exogenous lipids. Lipid-free media, similar to FASN inhibitors, caused growth-arrest. Although lipid-depleted cells have diminished amounts of CD36, LDLR and FABPs, they can still activate a restorative pathway that causes enhanced import of fluorophore-labeled FAs and LDLs. Overall, our data show that OC cells are strictly lipid-depend and exquisitely sensitive to FASN inhibitors, providing a strong rationale for developing anti-FASN strategies for clinical use against OC.Keywords
Funding Information
- Magistrat der Stadt Wien
- Medizinische Universität Wien
- Herzfelder'sche Familienstiftung
This publication has 34 references indexed in Scilit:
- New Synthetic Inhibitors of Fatty Acid Synthase with Anticancer ActivityJournal of Medicinal Chemistry, 2012
- A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell linesBreast Cancer Research, 2011
- Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian CancerMolecular Cancer Research, 2011
- Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growthNature Medicine, 2011
- The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cellsBreast Cancer Research and Treatment, 2010
- Novel Inhibitors of Fatty Acid Synthase with Anticancer ActivityClinical Cancer Research, 2009
- Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cellsBiochemical and Biophysical Research Communications, 2009
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targetsNature Reviews Drug Discovery, 2008
- Fatty acid synthase and the lipogenic phenotype in cancer pathogenesisNature Reviews Cancer, 2007
- Retinoids Control the Expression of c-erbB Receptors in Breast Cancer CellsBiochemical and Biophysical Research Communications, 1998